RBC Capital Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $108
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $106 to $108.
October 04, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its Outperform rating for Intra-Cellular Therapies and increased the price target from $106 to $108, indicating positive expectations for the stock.
The increase in price target from $106 to $108 by RBC Capital suggests a positive outlook for Intra-Cellular Therapies. The reaffirmation of the Outperform rating indicates confidence in the company's performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100